Innoviva, Inc. (NASDAQ:INVA) CFO Eric Desparbes sold 15,285 shares of Innoviva stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $13.28, for a total value of $202,984.80. Following the sale, the chief financial officer now directly owns 337,027 shares of the company’s stock, valued at $4,475,718.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of Innoviva, Inc. (NASDAQ INVA) traded down $0.16 during midday trading on Friday, reaching $13.26. The company’s stock had a trading volume of 302,432 shares, compared to its average volume of 1,049,057. The company has a current ratio of 6.71, a quick ratio of 6.71 and a debt-to-equity ratio of -2.59. The company has a market cap of $1,449.56, a price-to-earnings ratio of 15.43 and a beta of 2.51. Innoviva, Inc. has a 1-year low of $10.07 and a 1-year high of $14.87.

Innoviva (NASDAQ:INVA) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported $0.21 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.34 by ($0.13). The firm had revenue of $48.64 million for the quarter, compared to the consensus estimate of $57.18 million. Innoviva had a net margin of 52.91% and a negative return on equity of 33.55%. The company’s revenue for the quarter was up 46.0% on a year-over-year basis. During the same period last year, the firm earned $0.13 earnings per share. equities research analysts anticipate that Innoviva, Inc. will post 1.08 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally published by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.watchlistnews.com/eric-desparbes-sells-15285-shares-of-innoviva-inc-inva-stock/1724664.html.

INVA has been the subject of a number of research analyst reports. ValuEngine raised Innoviva from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Zacks Investment Research lowered Innoviva from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 16th. Cowen Inc set a $16.00 target price on Innoviva and gave the company a “buy” rating in a research report on Friday, July 28th. Robert W. Baird reaffirmed a “neutral” rating and set a $13.00 target price (up from $11.00) on shares of Innoviva in a research report on Thursday, July 27th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $15.00 target price on shares of Innoviva in a research report on Friday, July 28th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. Innoviva has an average rating of “Hold” and an average price target of $13.50.

Hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC raised its position in shares of Innoviva by 5.3% in the 2nd quarter. FMR LLC now owns 16,017,256 shares of the biotechnology company’s stock worth $205,021,000 after acquiring an additional 802,605 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Innoviva by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 7,459,616 shares of the biotechnology company’s stock worth $95,483,000 after acquiring an additional 226,969 shares in the last quarter. Sarissa Capital Management LP raised its position in shares of Innoviva by 3.2% in the 3rd quarter. Sarissa Capital Management LP now owns 3,600,705 shares of the biotechnology company’s stock worth $50,841,000 after acquiring an additional 110,000 shares in the last quarter. State Street Corp raised its position in shares of Innoviva by 14.7% in the 2nd quarter. State Street Corp now owns 2,717,255 shares of the biotechnology company’s stock worth $34,782,000 after acquiring an additional 348,584 shares in the last quarter. Finally, Northern Trust Corp raised its position in shares of Innoviva by 11.3% in the 2nd quarter. Northern Trust Corp now owns 1,243,046 shares of the biotechnology company’s stock worth $15,911,000 after acquiring an additional 126,246 shares in the last quarter. 72.14% of the stock is owned by institutional investors and hedge funds.

About Innoviva

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Receive News & Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.